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Prevalence of steatosis and fibrosis in young adults in the UK: 
a population-based study
Kushala W M Abeysekera, Gwen S Fernandes, Gemma Hammerton, Andrew J Portal, Fiona H Gordon, Jon Heron, Matthew Hickman
Summary
Background The estimated worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) in adults is 25%; 
however, prevalence in young adults remains unclear. We aimed to identify the prevalence of steatosis and fibrosis in 
young adults in a sample of participants recruited through the Avon Longitudinal Study of Parents and Children 
(ALSPAC), based on transient elastography and controlled attenuation parameter (CAP) score.
Methods In this population-based study, we invited active participants of the ALSPAC cohort to our Focus@24+ 
clinic at the University of Bristol (Bristol, UK) between June 5, 2015, and Oct 31, 2017, for assessment by transient 
elastography with FibroScan, to determine the prevalence of steatosis and fibrosis. FibroScan data were collected on 
histologically equivalent fibrosis stage (F0-F4) and steatosis grade (S0-S3); results with an IQR to median ratio of 
30% or greater were excluded for median fibrosis results greater than 7·1 kPa, and CAP scores for steatosis were 
excluded if less than ten valid readings could be obtained. Results were collated with data on serology (including 
alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase) and exposures of interest: alcohol 
consumption (via the Alcohol Use Disorder Identification Test for Consumption [AUDIT-C] and the Diagnostic and 
Statistical Manual of Mental Disorders-5 criteria for alcohol use disorder), body-mass index (BMI), waist-to-height 
ratio, socioeconomic status (based on predefined ALSPAC markers), and sex. We used logistic regression models to 
calculate odds ratios (ORs) for the effect of exposures of interest on risk of steatosis and fibrosis, after dichotomising 
the prevalences of fibrosis and steatosis and adjusting for covariates (excessive alcohol intake [hazardous drinking, 
AUDIT-C score ≥5; or harmful drinking, evidence of alcohol use disorder], social class, smoking, and BMI).
Findings 10 018 active ALSPAC participants were invited to our Focus@24+ clinic, and 4021 attended (1507 men and 
2514 women), with a mean age of 24·0 years (IQR 23·0–25·0). 3768 CAP scores were eligible for analysis. 
780 (20·7% [95% CI 19·4–22·0]) participants had suspected steatosis (S1–S3; ≥248 dB/m), with 377 (10·0%) 
presenting with S3 (severe) steatosis (≥280 dB/m). A BMI in the overweight or obese range was positively associated 
with steatosis when adjusted for excessive alcohol consumption, social class, and smoking (overweight BMI: 
OR 5·17 [95% CI 4·11–6·50], p<0·0001; obese BMI: 27·27 [20·54–36·19], p<0·0001). 3600 participants had valid 
transient elastography results for fibrosis analysis. 96 participants (2·7% [95% CI 2·2–3·2]) had transient 
elastography values equivalent to suspected fibrosis (F2–F4; ≥7·9 kPa), nine of whom had values equivalent to 
F4 fibrosis (≥11·7 kPa). Individuals with alcohol use disorder and steatosis had an increased risk of fibrosis when 
adjusted for smoking and social class (4·02 [1·24–13·02]; p=0·02).
Interpretation One in five young people had steatosis and one in 40 had fibrosis around the age of 24 years. The risk 
of fibrosis appears to be greatest in young adults who have harmful drinking patterns and steatosis. A holistic 
approach to the UK obesity epidemic and excessive drinking patterns is required to prevent an increasing health-care 
burden of adults with advanced liver disease in later life.
Funding Medical Research Council UK, Alcohol Change UK, David Telling Charitable Trust.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) has an 
estimated worldwide prevalence in adults of 
approximately 25%.1 The disease is recognised as a 
spectrum of conditions, ranging from simple steatosis to 
non-alcoholic steatohepatitis (NASH), and ultimately 
cirrhosis. Worldwide, NASH pre valence in adults is 
estimated to be 6% in developed countries, with up to 
40% of these individuals progressing to advanced 
fibrosis.1
This high prevalence has serious implications: almost 
a fifth of new hepato cellular carcinoma cases in 
developed countries are attributable to NAFLD.2 In 
the UK, NASH-related cirrhosis is among the most 
common indications for liver transplantation.3 An 
increased pool of steatotic donor livers has ramifications 
for recipients, with primary graft non-function and dys-
function increasingly associated with graft steatosis.4
The rise in the prevalence of NAFLD mirrors that of 
obesity and metabolic syndrome, and young adults with 
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For the website of the ALSPAC 
see www.bristol.ac.uk/alspac/
researchers/our-data
NAFLD represent the next major public health challenge 
for health services.5 Prospective cohort popu lation 
studies in an adolescent setting (17–18 years) have 
estimated the prevalence of NAFLD to be between 2·5% 
and 12·8% in developed countries from liver ultrasound 
data.6,7 Although liver biopsy is considered the gold 
standard for NAFLD assessment, it is unethical in large 
population studies, because of a risk of serious adverse 
events following the procedure.8
To our knowledge, the largest study to analyse NAFLD 
prevalence in young adults used the US National Health 
and Nutrition Examination Survey. This study postulated 
a prevalence of 25% in people aged 18–35 years in 
the USA, under criteria for NAFLD of a body-mass index 
(BMI) greater than 25 kg/m², and an alanine amino-
transferase (ALT) concentration greater than 30 U/L in 
men and 19 U/L in women.9
Transient elastography, as a fast, simple, safe, and 
accurate technique, is considered the non-invasive 
standard for assessing liver fibrosis.10–12 To date, no 
population studies have looked into the prevalence of 
fibrosis and steatosis in young adults assessed by 
transient elastography.
The Avon Longitudinal Study of Parents and Children 
(ALSPAC) is a general population, prospective birth 
cohort study of children born in the greater Bristol area 
of the UK, during 1991 and 1992. In this cohort, 
1874 participants were assessed for NAFLD in their late 
teens (mean age 17·9 years), with a NAFLD prevalence 
of 2·5% identified by ultrasound.6 In the current study, 
we aimed to identify the prevalence of steatosis and 
fibrosis in young adults from the unselected, general 
population birth cohort of ALSPAC by use of transient 
elastography.
Methods
Study design and population
We did a population-based study of young adults re cruited 
through ALSPAC. ALSPAC is a prospective birth cohort 
study based at the University of Bristol (Bristol, UK) in 
southwest England.13,14 The study website contains details 
of all available data through a fully searchable data 
dictionary and variable search tool. Briefly, ALSPAC 
recruited 15 454 pregnant women with expected delivery 
dates between April 1, 1991, and Dec 31, 1992, in the greater 
Bristol area.15 Ethical approval for the study was obtained 
from the ALSPAC Ethics and Law Committee and the 
National Research Ethics Service Committee South 
West—Frenchay (14/SW/1173 ALSPAC Focus@24+). 
Consent for use of biological samples in the current study 
was collected from offspring participants in accordance 
with the Human Tissue Act (2004). Informed consent for 
use of data collected with questionnaires and clinics was 
obtained from the offspring participants following the 
recommendations of the ALSPAC Ethics and Law 
Committee.
We invited active offspring participants of ALSPAC13 by 
letter and email to our Focus@24+ clinic at the University 
of Bristol between June 5, 2015, and Oct 31, 2017, for 
assess ment by transient elastography (FibroScan 502 
Touch; Echosens, Paris, France), with measurement of 
controlled atte nuation parameter (CAP), as standardised 
non-invasive measures for assessment of fibrosis and 
quantification of steatosis in NAFLD.10,16 Study data were 
Research in context
Evidence before this study
Non-alcoholic fatty liver disease (NAFLD) affects approximately 
a quarter of adults in developed countries, a substantial 
proportion of whom are at risk of developing liver failure and 
liver cancer, and an increased risk of death related to heart 
disease. One of the largest studies to analyse prevalence of 
NAFLD in young adults used data from the National Health and 
Nutrition Examination Survey. The estimated prevalence of 
suspected NAFLD in adults aged 18–35 years was 25%, under 
the criteria for NAFLD of an alanine aminotransferase 
concentration greater than 30 IU/L in men and greater than 
19 IU/L in women, and a body-mass index greater than 
25 kg/m²; however, these criteria are broad. To date, no study 
has used imaging to screen young adults and establish the true 
prevalence of NAFLD in this sparsely studied age group.
Added value of this study
This study is, to the best of our knowledge, the first to determine 
the prevalence of NAFLD in young adults with use of transient 
elastography, in an age group in which NAFLD burden is poorly 
characterised. The added value of our use of the Avon 
Longitudinal Study of Parents and Children (ALSPAC) cohort is 
that, as the most phenotyped birth cohort worldwide, this group 
of young adults has already been assessed for NAFLD between 
the ages of 17 and 18 years, which acts as a comparator.
Implications of all the available evidence
We identified that around 20% of young adults in our cohort 
had steatosis of grade S1 or higher around the age of 24 years. 
One in 40 also had evidence of liver fibrosis, with participants at 
greatest risk of fibrosis being those with harmful drinking 
patterns and evidence of steatosis. Patients identified with 
steatosis and early fibrosis as young adults might present in 
earlier decades of life with advanced liver disease, placing 
increased strain on inpatient and transplant services. 
This outcome could have wide implications in the context of 
the national obesity epidemic in the UK. Increased public health 
interventions are required to tackle the obesity epidemic and 
excessive drinking in young adults, to attenuate their risk of 
NAFLD and alcohol-related liver disease, and therefore reduce 
the health-care burden of advanced liver disease.
Articles
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collected and managed with REDCap electronic data 
capture tools hosted at the University of Bristol.17
Assessment of outcomes
All participants attending the Focus@24+ clinic were 
asked to fast for a minimum of 6 h, or overnight, before 
blood tests and subsequent transient elastography. Our 
serology analyses included liver function tests for ALT, 
aspartate aminotransferase (AST), and γ-glutamyl 
transferase (GGT). Lipid profiles were also taken, of 
cholesterol, triglycerides, LDL, VLDL, and HDL. Serum 
concentrations of glucose and insulin were also used to 
calculate homoeostasis model assessment for insulin 
resistance (HOMA-IR) scores with the equation (fasting 
insulin [µU/mL] × fasting glucose [mmol/L])/22·5.18,19
After phlebotomy, transient elastography was offered to 
all participants by trained field workers in the clinic. Ten 
valid readings were required to derive a CAP score and 
fibrosis result. The M probe was used initially unless the 
machine indicated use of the XL probe. In line with 
manufacturer in structions, cut-off values used for the 
M probe and XL probe were the same.20
Cut-off values for CAP score for different grades of 
steatosis (S0–S3) were derived from a meta-analysis on 
CAP technology: S0 was defined as a score of less than 
248 dB/m (<10% steatosis); S1 as a score of 248 to less than 
268 dB/m (10%–<33% steatosis [mild]); S2 as a score of 
268 to less than 280 dB/m (33%–<66% steatosis [moderate]); 
and S3 as a score of 280 dB/m or more (≥66% steatosis 
[severe]).16 CAP scores of 248 dB/m or greater (≥S1) were 
considered as suspected steatosis. Participants’ CAP scores 
were considered eligible for analysis if ten valid readings 
(100–400 dB/m) could be obtained.16
In the context that NAFLD is more common than 
alcohol-related liver disease in adolescents, and that 
NAFLD is present in more than 25% of the global adult 
population,1 when analysing the cohort as a whole, 
transient elastography cut-off values for NAFLD related 
to the METAVIR scoring system10 were used for fibrosis 
staging (F0–F4: F0–F1, <7·9 kPa; F2, 7·9 to <8·8 kPa; F3, 
8·8 to <11·7 kPa; and F4, ≥11·7 kPa).10,21 Participants with 
a transient elastography value of 7·9 kPa or greater (≥F2) 
were considered to have suspected fibrosis. If a 
participant’s median fibrosis result was greater than 
7·1 kPa, the IQR to median ratio had to be less than 30% 
to be considered valid.22
Assessment of exposures
Participants’ alcohol consumption was assessed with 
questionnaires at private computer terminals. Questions 
were based on the Alcohol Use Disorder Identification 
Test for Consumption (AUDIT-C), and the Diagnostic and 
Statistical Manual of Mental Disorders-5 criteria for 
alcohol use disorder,23 from which we derived an AUDIT-C 
score and determined the presence of alcohol use disorder. 
Participants were then stratified according to a three-
category ordinal variable, separating low-risk drinkers 
(AUDIT-C score <5 and absence of alcohol use disorder), 
hazardous drinkers (AUDIT-C score of ≥5 and absence of 
alcohol use disorder), and harmful drinkers (evidence of 
alcohol use disorder).
We calculated BMI and waist-to-height ratio as surro-
gate markers of adiposity.24 Participants with metabolic 
syndrome were identified according to the diagnostic 
criteria of the Adult Treatment Panel III/American Heart 
Institute/National Heart, Lung, and Blood Institute 
(ATPIII/AHA/NHLBI) scoring system, which involves 
elevated waist circumference, elevated triglycerides, low 
HDL, elevated blood pressure, and elevated fasting 
glucose.25 Participants were recor ded as smokers if they 
had smoked in the 30 days before the clinic visit, 
including those who had used e-cigarettes. At the time 
mothers were recruited, the ALSPAC used three markers 
of socioeconomic status: parental social class, maternal 
education level achieved, and parental income.26,27 All 
three variables were interrogated as exposures to identify 
whether social position was associated with our outcome 
measures.
We requested participants to specify all current 
medications in writing on attendance to the clinic, along 
with indication for treatment, and self-nominated text 
responses were logged.
Statistical analysis
Univariable linear regression models were used to 
examine differences across the ordinal categories 
of steatosis grade and fibrosis stage. Exposures of 
interest were BMI, waist-to-height ratio, alcohol con-
sumption, socioeconomic status, and sex. When analysing 
fibrosis prevalence, we interrogated the exposure of 
steatosis, and combined harmful alcohol consumption (ie, 
alcohol use disorder) and steatosis. Likelihood ratio tests 
were used to assess the adequacy of a model in which 
change was restricted to be linear (ie, involving a single 
exposure and outcome of interest). Multivariable logistic 
regression was done after dicho tomising the prevalences 
of fibrosis and steatosis, following which odds ratios 
(ORs) were calculated for exposures previously shown to 
be associated with the development of steatosis (BMI, 
waist-to-height ratio, alcohol consumption, maternal 
education [as a surrogate marker of socioeconomic status], 
and sex1,5) and fibrosis (alcohol consumption, steatosis, 
and sex3,21), while adjusting for covariates (excessive 
alcohol intake [hazardous and harmful drinking], social 
class, smoking, and BMI). Statistical analysis was done 
with Stata/MP (version 15.1). In line with the ALSPAC 
confidentiality policy, any analysed groups with less than 
five participants are expressed as n<5. This number can 
include zero.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
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the data in the study and had final responsibility for the 
decision to submit for publication.
Results
5436 original offspring participants of the ALSPAC have 
been lost to study attrition over the past three decades 
and did not have sufficient auxiliary information from 
which a response could be imputed.13 10 018 active 
ALSPAC participants were invited to our Focus@24+ 
clinic. Of those who were invited, 4021 (40·1%) attended 
(figure 1). Characteristics of participants who attended 
the clinic are shown in table 1. This population had a 
mean age of 24·0 years (IQR 23·0–25·0), with a range of 
22–26 years, and comprised 1507 men and 2514 women. 
In total, 421 (10·5%) participants were excluded. Reasons 
for exclusion were not accepting the transient elasto-
graphy session (n=107), withdrawal of consent from the 
current study (n=38), insufficient information for fibrosis 
or CAP measurement (n=182), or a transient elastography 
result with an IQR to median ratio of 30% or greater 
(n=94; figure 1).
In our check of current medications, no participants 
reported having viral hepatitis or to be taking nucleos(t)
ide analogues or direct-acting antivirals. Autoimmune 
hepatitis requiring azathioprine, and overlap syndrome 
with autoimmune hepatitis and primary sclerosing cho-
langitis requiring prednisolone, mycophenolate mofetil, 
or ursodeoxycholic acid were reported in less than five 
participants each, but these individuals were not excluded 
on the basis of this being a general population study. 
23 participants were taking insulin for type 1 diabetes. No 
participants were known to have type 2 diabetes.
Table 2 shows participant characteristics in relation 
to steatosis grade: 3768 had valid CAP scores (range 
100–400 dB/m; mean 209·2 dB/m [SD 53·1]; 2341 women 
and 1427 men). 780 (20·7% [95% CI 19·4–22·0]) of the 
3768 participants had S1 or greater steatosis; 377 (48·3%) 
of this group had S3 (severe) steatosis.
BMI was positively associated with increasing steatosis 
grade (p<0·0001), with the median BMI being in the 
overweight range (25 to <30 kg/m²) for S1 and S2 and the 
obese range (≥30 kg/m²) for S3 (table 2). As steatosis 
grade increased, the proportion of participants with 
obesity increased to 56·2% in participants with S3 grade 
steatosis (p<0·0001; table 2 and figure 2). Overall, a 
Figure 1: Participant flow chart
*182 with insufficient data for fibrosis measurement and 108 with insufficient 
data for CAP measurement; reasons included not achieving ten valid scan 
measurements or missing data.
10 018 ALSPAC participants invited to Focus@24+ clinic
4021 attended the clinic
3600 with a valid fibrosis score
3768 with a valid CAP score
5997 did not attend the clinic
421 excluded from analysis
 107 did not attend the transient
  elastography session
 38 withdrew consent from the 
 current study
 182 with insufficient information*
 94 with an invalid transient 
  elastography result on fibrosis





Age, years 24·0 (23·0–25·0)
Parental social class*†
IV–V (partly skilled and unskilled occupation) 111 (3·2%)
III (non-manual and manual occupation) 1100 (31·7%)
II (managerial and technical occupation) 1587 (45·7%)
I (professional occupation) 673 (19·4%)
Parental income*†
Lowest 20% 428 (13·0%)
Second quintile 571 (17·3%)
Third quintile 663 (20·1%)
Fourth quintile 769 (23·3%)
Highest 20% 869 (26·3%)
Maternal education (highest level achieved)†
Lower than O-levels 615 (17·0%)
O-levels 1223 (33·9%)





Normal (AUDIT-C score <5) 1813 (45·1%)
Hazardous (AUDIT-C score ≥5) 1697 (42·2%)
Harmful (alcohol use disorder) 511 (12·7%)
BMI†
Underweight (<18·5 kg/m²) 119 (3·0%)
Normal weight (18·5 to <25 kg/m²) 2323 (58·4%)
Overweight (25 to <30 kg/m²) 1002 (25·2%)
Obese (≥30 kg/m²) 533 (13·4%)
Waist-to-height ratio†
Normal adiposity (<0·5) 2856 (72·0%)
Increased adiposity (≥0·5) 1108 (28·0%)
Data are n (% of available data), median (IQR), or mean (SD). ALSPAC=Avon 
Longitudinal Study of Parents and Children. AUDIT-C=Alcohol Use Disorder 
Identification Test-C. BMI=body-mass index. *As defined in the ALSPAC cohort.13,14  
†Missing data: parental social class, n=550; parental income, n=721; maternal 
education, n=408; smoking status, n=142; BMI, n=44; waist-to-height ratio, n=57. 
Table 1: Characteristics of ALSPAC participants who attended the 
Focus@24+ clinic
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greater porportion of women had obesity compared with 
men (372 [15·0%] of 2479 vs 161 [10·7%] of 1498 with 
available data; not shown). Waist-to-height ratio was also 
positively associated with increasing steatosis grade 
(p<0·0001; table 2). Overall, a slightly greater proportion 
of men had increased adiposity (waist-to-height ratio 
≥0·5) compared with women (428 [28·6%] of 1495 vs 680 
[27·5%] of 2469 with available data; not shown). ALT, 
AST, and GGT were positively associated with increasing 
steatosis grade (all p<0·0001; table 2). Of participants 
with steatosis, 371 (60·2%) of 616 with available ALT data 
had an ALT concentration of less than 30 IU/L. In 
participants with valid data, 339 (59·9%) of 566 had 
steatosis without fibrosis and ALT less than 30 IU/L.
HOMA-IR also increased with rising steatosis grade 
(p<0·0001; table 2). Similarly, cholesterol, triglyceride, 
LDL, and VLDL were positively associated with steatosis 
(all p<0·0001), whereas HDL showed a negative association 
(p<0·0001). Metabolic syndrome was positively associated 
with steatosis grade (p<0·0001), with 86 (50·0%) 
of 172 participants with metabolic syndrome having 
S3 steatosis.
S0 (n=2988; 79·3%) S1 (n=281; 7·5%) S2 (n=122; 3·2%) S3 (n=377; 10·0%) p value
Sex ·· ·· ·· ·· <0·0001†
Male (n=1427) 1054 (73·8%) 128 (9·0%) 54 (3·8%) 191 (13·4%) ··
Female (n=2341) 1934 (82·6%) 153 (6·5%) 68 (2·9%) 186 (7·9%) ··
Parental social class‡ ·· ·· ·· ·· 0·75†
IV–V (partly skilled and unskilled occupation; 
n=103)
80 (77·7%) 10 (9·7%) 5 (4·9%) 8 (7·8%) ··
III (non-manual and manual occupation; 
n=1020)
789 (77·4%) 77 (7·5%) 37 (3·6%) 117 (11·5%) ··
II (managerial and technical occupation; 
n=1492)
1192 (79·9%) 110 (7·4%) 40 (2·7%) 150 (10·1%) ··
I (professional occupation; n=641) 524 (81·7%) 49 (7·6%) 22 (3·4%) 46 (7·2%) ··
Smoker§ ·· ·· ·· ·· 0·71†
No (n=2528) 2008 (79·4%) 188 (7·4%) 77 (3·0%) 255 (10·1%) ··
Yes (n=1104) 875 (79·3%) 84 (7·6%) 40 (3·6%) 105 (9·5%) ··
Alcohol consumption ·· ·· ·· ·· 0·26†
Low risk (AUDIT-C score <5; n=1693) 1317 (77·8%) 130 (7·7%) 66 (3·9%) 180 (10·6%) ··
Hazardous (AUDIT-C score ≥5; n=1586) 1281 (80·8%) 110 (6·9%) 44 (2·8%) 151 (9·5%) ··
Harmful (alcohol use disorder; n=489) 390 (79·8%) 41 (8·4%) 12 (2·5%) 46 (9·4%) ··
BMI, kg/m² 22·9 (21·0–25·3) 26·6 (24·1–29·9) 27·7 (25·1–30·7) 31·0 (27·2–35·2) <0·0001¶
Obese participants (BMI ≥30 kg/m²) 162 (5·4%) 67 (24·0%) 37 (30·3%) 212 (56·2%) <0·0001¶
Waist-to-height ratio 0·45 (0·42–0·48) 0·50 (0·47–0·55) 0·51 (0·48–0·56) 0·57 (0·52–0·63) <0·0001¶
Homoeostasis model assessment for insulin 
resistance score (reference range <1·68)
1·60 (1·13–2·23) 2·31 (1·56–3·78) 2·41 (1·54–3·88) 3·60 (2·24–5·38) <0·0001¶
Alanine aminotransferase, IU/L (reference range 
10–35 IU/L)
19·4 (14·8–26·8) 21·4 (16·1–30·8) 22·4 (17·4–34·8) 30·5 (20·5–51·9) <0·0001¶
Aspartate aminotransferase, 
IU/L (reference range 10–35 IU/L)
23·9 (20·4–28·9) 24·0 (20·1–28·2) 24·9 (20·9–29·1) 27·5 (22·7–35·7) <0·0001¶
γ-Glutamyl 
transferase, IU/L (reference range <40 IU/L) 
15·0 (12·0–20·0) 18·0 (13·0–26·0) 18 (14·0–26·0) 23·0 (16·0–38·0) <0·0001¶
Cholesterol, mmol/L (reference range 
<5·2 mmol/L)
4·4 (0·8) 4·5 (0·8) 4·6 (0·8) 4·7 (0·9) <0·0001¶
Triglycerides, mmol/L (reference range 
<1·7 mmol/L)
0·8 (0·6–1·1) 0·9 (0·6–1·2) 1·1 (0·8–1·5) 1·2 (0·8–1·8) <0·0001¶
LDL, mmol/L 2·4 (0·7) 2·6 (0·7) 2·7 (0·7) 2·8 (0·9) <0·0001¶
VLDL, mmol/L 0·4 (0·3–0·5) 0·4 (0·3–0·6) 0·5 (0·4–0·7) 0·5 (0·4–0·8) <0·0001¶
HDL, mmol/L (reference range >1·45 mmol/L) 1·6 (0·4) 1·4 (0·4) 1·3 (0·3) 1·2 (0·3) <0·0001¶
Metabolic syndrome (≥3 of 5 criteria||; n=172) 48 (27·9%) 23 (13·4%) 15 (8·7%) 86 (50·0%) <0·0001†
Data are n (% of available data), mean (SD; normally distributed variables), or median (IQR; non-normally distributed variables); numbers reflect available data and therefore do 
not always reflect the total population (data missing on 512 participants across all categories). AUDIT-C=Alcohol Use Disorder Identification Test-C. BMI=body-mass index. 
*Grading based on controlled attenuation parameter cut-off values in decibels per metre (dB/m): S0, <248 dB/m; S1, 248–<268 dB/m; S2, 268–<280 dB/m; and S3, ≥280 dB/m.16 
†Pearson’s χ² test. ‡Classes defined as in the ALSPAC cohort;13,14  results on other socioeconomic markers not displayed because of a high proportion of missing data. §Defined as 
participants who had smoked ≤30 days before the clinic visit (including e-cigarette use). ¶Likelihood ratio test following univariable regression. ||Metabolic syndrome criteria: 
(1) male waist circumference ≥102 cm or female waist circumference ≥88 cm; (2) triglyceride concent ration ≥1·7mmol/L; (3) HDL in men <1·93 mmol/L or in women <1·3mmol/L; 
(4) systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg; and (5) fasting glucose ≥5·6 mmol/L.25 
Table 2: Serology and exposure factors according to steatosis grade (S0–S3)* in analysed participants (n=3768)
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No association was found between steatosis grade and 
parental social class (table 2), with similar findings for 
other markers of socioeconomic status (parental income 
and maternal education; not shown). Additionally, 
smoking and alcohol consumption had no association 
with steatosis grade (table 2).
On regression analyses, participants with a BMI in the 
obese range had a five times greater risk of steatosis than 
those with a BMI in the overweight range, following 
adjustment for excessive alcohol intake (ie, hazardous 
and harmful consumption), smoking, and social class 
(table 3). An increased risk of steatosis was also seen for 
adiposity with the surrogate marker of waist-to-height 
ratio, adjusted for the same covariates (table 3). Women 
had proportionally less steatosis than men, after 
adjusting for BMI, excessive alcohol intake, social class, 
and smoking (table 3). Maternal attainment of higher 
education appeared to be associated with a reduced risk 
of steatosis on unadjusted analysis, but after adjustment 
for BMI, excessive alcohol intake, and smoking, this 
relationship was lost (table 3).
On evaluation of alcohol-related steatosis, 489 (13·0%) 
of 3768 participants showed evidence of harmful alcohol 
consumption (ie, alcohol use disorder), 99 (20·2%) of 
whom had steatosis. On unadjusted analysis, no evidence 
was found of an increased risk of steatosis with harmful 
alcohol intake (table 3).
3600 participants had valid transient elastography 
results (range 1·3–44·5 kPa; mean 4·7 kPa [SD 1·5]; 
table 4). 96 (2·7% [95% CI 2·2–3·2]) of the participants 
had transient elastography values equivalent to METAVIR 
F2–F4 fibrosis (42 with F2 fibrosis [≥7·9 kPa], 45 with 
F3 fibrosis [≥8·8 kPa], and nine with F4 fibrosis 
[≥11·7 kPa]). CAP score was positively associated with 
increasing fibrosis stage (p<0·0001; table 4), with the nine 
participants with suspected F4 fibrosis having a mean 
CAP score of 283·4 dB/m, equating to S3 steatosis. 
Similar positive associations with fibrosis stage were seen 
with BMI (p<0·0001) and waist-to-height ratio (p=0·009); 
although the median BMI in the suspected F4 group was 
only borderline overweight (table 4). No association was 










Normal 171/2206 (7·8%) Reference ·· Excessive alcohol intake†, social class, smoking Reference ··
Overweight 285/936 (30·4%) 5·34 (4·33–6·60) <0·0001 ·· 5·17 (4·11–6·50) <0·0001
Obese 316/478 (66·1%) 23·8 (18·61–30·47) <0·0001 ·· 27·27 (20·54–36·19) <0·0001
Waist-to-height ratio*
Normal adiposity (<0·5) 254/2718 (9·3%) Reference ·· Excessive alcohol intake†, social class, smoking Reference
Increased adiposity (≥0·5) 517/1007 (51·3%) 10·24 (8·56–12·24) <0·0001 ·· 10·73 (8·79–13·10) <0·0001
Alcohol consumption†
Low risk 376/1693 (22·2%) Reference ·· Social class, smoking Reference ··
Hazardous (AUDIT-C score ≥5) 305/1586 (19·2%) 0·83 (0·70–0·99) 0·04 ·· 0·87 (0·71–1·05) 0·14
Harmful (alcohol use disorder) 99/489 (20·2%) 0·89 (0·69–1·14) 0·35 ·· 0·92 (0·69–1·22) 0·57
Maternal education
Primary level 149/573 (26·0%) Reference ·· BMI, excessive alcohol intake†, smoking Reference ··
Secondary level 257/1147 (22·4%) 0·82 (0·65–1·04) 0·10 ·· 1·03 (0·77–1·37) 0·85
Higher education 298/1673 (17·8%) 0·62 (0·49–0·77) <0·0001 ·· 1·06 (0·81–1·40) 0·66
Sex
Male 373/1427 (26·1%) Reference ·· BMI, excessive alcohol intake†, social class, smoking Reference ··
Female 407/2341 (17·4%) 0·59 (0·51–0·70) <0·0001 ·· 0·46 (0·37–0·57) <0·0001
OR=odds ratio. BMI=body-mass index. AUDIT-C=Alcohol Use Disorder Identification Test-C. *Threshold for normal and increased adiposity as defined previously.24  †According to AUDIT-C score and the 
Diagnostic and Statistical Manual of Mental Disorders-5 criteria for alcohol use disorder;23 excessive intake defined as hazardous or harmful consumption.
Table 3: Exposures associated with the presence of steatosis in analysed participants (n=3768)
Figure 2: Distribution of BMI categories across steatosis grade
Steatosis grade was derived from measurement of controlled attenuation 
parameter. Percentages represent obese participants at each grade.
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On multivariable regression, female sex was associated 
with a significant reduction in the risk of fibrosis, after 
adjusting for BMI, excessive alcohol intake, smoking, and 
social class (table 5). Harmful alcohol consumption had 
some association with increased risk of fibrosis when 
adjusted for CAP, BMI, smoking, and social class 
(table 5). After adjusting for excessive alcohol intake, 
BMI, smoking, and social class, no association was found 
between increasing steatosis grade and fibrosis (table 5). 
No interaction was identified between steatosis and 
alcohol in the context of fibrosis (interaction parameter 
1·70 [95% CI 0·56–5·16]; p=0·35). However, concurrent 
alcohol use disorder and steatosis increased the risk of 
fibrosis (after adjustment for smoking and social class), 
compared with steatosis or alcohol use disorder alone 
(table 5).
ALT, AST, and GGT appeared to be positively associated 
with increasing fibrosis stage (all p<0·0001; table 4). 
However, in our multivariable regression models with 
ALT, AST, and GGT as the dependent variables, and 
fibrosis stage as the independent variable, with 
adjustment for CAP score, no such relationships were 
identified (ALT, p=0·16; AST, p=0·27; and GGT, p=0·46). 
Thus, the changes in liver function tests with increasing 
fibrosis stage on univariable regression were probably 
dependent on CAP in the context of suspected NAFLD. 
No associations were found between fibrosis stage and 
lipid profile, HOMA-IR, smoking status, or social class 
(table 4).
94 participants had transient elastography values with 
an elevated IQR to median ratio (≥30%). These 
participants had higher CAP scores than the group with 
F0–F1 (n=3504; 97·3%) F2 (n=42; 1·2%) F3 (n=45; 1·3%) F4 (n=9; 0·3%) p value
Sex ·· ·· ·· ·· 0·002†
Male 1337 27 22 <5 ··
Female 2167 15 23 <5 ··
Parental social class‡ ·· ·· ·· ·· 0·22†
IV-V (partly and unskilled occupation) 99 <5 <5 <5 ··
III (non-manual and manual occupation) 961 9 9 <5 ··
II (managerial and technical occupation) 1401 16 19 <5 ··
I (professional occupation) 613 <5 9 <5 ··
Smoker§ ·· ·· ·· ·· 0·12†
No 2359 30 25 9 ··
Yes 1018 10 16 <5 ··
Alcohol consumption ·· ·· ·· ·· 0·092†
Low risk (AUDIT-C score <5) 1573 17 16 <5 ··
Hazardous (AUDIT-C score ≥5) 1481 13 22 <5 ··
Harmful (alcohol use disorder) 450 12 7 <5 ··
Controlled attenuation parameter score (dB/m) 208·5 (52·2) 219·8 (57·2) 221·1 (57·5) 283·4 (96·1) <0·0001¶
BMI, kg/m² 23·6 (21·5–26·7) 23·6 (21·9–26·5) 25·3 (22·2–27·9) 25·5 (22·9–40·9) <0·0001¶
Obese participants (BMI ≥30 kg/m²) 407 5 9 <5 <0·0001
Waist-to-height ratio 0·46 (0·43–0·50) 0·45 (0·41–0·50) 0·46 (0·43–0·51) 0·48 (0·44–0·69) 0·009¶
Homoeostasis model assessment for insulin resistance score (reference 
range <1·68)
1·7 (1·2–2·5) 1·6 (1·1–2·5) 1·7 (1·3–3·1) 1·3 (0·7–5·9) 0·16¶
Alanine aminotransferase, IU/L (reference range 10–35 IU/L) 20·4 (15·3–29·0) 21·3 (17·7–35·6) 27·6 (17·9–42·2) 33·1 (29·2–45·3) <0·0001¶
Aspartate aminotransferase, IU/L (reference range 10–35 IU/L) 24·1 (20·6–29·1) 26·2 (21·2–30·5) 26·2 (21·5–36·4) 37·7 (27·4–43·4) <0·0001¶
γ-Glutamyl transferase,  IU/L (reference range <40 IU/L) 16·0 (12·0–22·0) 22·0 (17·0–32·0) 19·0 (15·0–31·0) 24·5 (20·0–40·0) <0·0001¶
Cholesterol, mmol/L (reference range <5·2 mmol/L) 4·4 (0·8) 4·4 (1·0) 4·3 (1·1) 4·6 (0·8) 0·47¶
Triglycerides, mmol/L (reference range <1·7 mmol/L) 0·8 (0·6–1·1) 0·9 (0·6–1·1) 0·8 (0·7–1·0) 0·7 (0·6–1·3) 0·36¶
LDL, mmol/L 2·4 (0·8) 2·4 (1·1) 2·3 (0·9) 2·8 (0·9) 0·51¶
VLDL, mmol/L 0·4 (0·3–0·5) 0·4 (0·3–0·5) 0·4 (0·3–0·4) 0·3 (0·3–0·6) 0·25¶
HDL, mmol/L (reference range >1·45 mmol/L) 1·6 (0·4) 1·5 (0·5) 1·6 (0·4) 1·4 (0·4) 0·94¶
Metabolic syndrome (≥3 of 5 criteria||; n=162) 153 <5 <5 <5 0·20†
Data are n, mean (SD; normally distributed variables), or median (IQR; non-normally distributed variables); numbers reflect available data and therefore do not always reflect the total population (data missing on 
526 participants across all categories). Any analysed groups with less than five participants are expressed as n<5 in line with the ALSPAC confidentiality policy (percentages not provided for the same reason). 
AUDIT-C=Alcohol Use Disorder Identification Test-C. BMI=body-mass index. *Staging based on transient elastography cut-off values: F0–F1, <7·9 kPa; F2, 7·9 to <8·8 kPa; F3, 8·8 to <11·7 kPa; and F4, ≥11·7 kPa. 
†Pearson’s χ² test. ‡Classes defined as in the ALSPAC cohort;13,14 results on other socioeconomic markers not displayed because of a high proportion of missing data. §Defined as participants who had smoked 
≤30 days before the clinic visit (including e-cigarette use).¶Likelihood ratio test following univariable regression. ||Metabolic syndrome criteria: (1) male waist circumference ≥102 cm or female waist 
circumference ≥88 cm; (2) triglyceride concentration ≥1·7mmol/L; (3) HDL in men <1·93 mmol or in women <1·3mmol/L; (4) systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg; and 
(5) fasting glucose ≥5·6 mmol/L.25
Table 4: Serology and exposure factors according to fibrosis stage (F0–F4)* in analysed participants (n=3600)
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IQR to median ratios within the valid range, and higher 
BMI and adiposity (appendix).
Discussion
In our general population cohort sampled from the 
ALSPAC cohort, around one in five young adults had 
steatosis, and one in 40 had liver fibrosis. Our estimate of 
NAFLD is lower than that in the previous largest attempt 
to analyse prevalence in young adults from National 
Health and Nutrition Examination Survey data,9 which 
found a prevalence of 25% in people aged 18–35 years, 
albeit with a different assessment modality. In our study, 
BMI and adiposity were independent predictors of 
steatosis despite adjusting for excessive alcohol 
consumption. To the best of our knowledge, the prevalence 
of steatosis detected with CAP measurement in our birth 
cohort is one of the first attempts to assess prevalence of 
NAFLD in young adults in the UK.
Although 96 participants were identified with suspected 
F2–F4 fibrosis, these cases cannot be solely attributed to 
NAFLD. No associations were found between steatosis 
and metabolic syndrome, harmful alcohol use (ie, alcohol 
use disorder), or fibrosis; however, participants with 
steatosis and alcohol use disorder had a four times greater 
risk of developing fibrosis, when adjusted for confounders. 
These patients could represent participants with both 
alcohol-related and non-alcoholic fatty liver disease.
In a similar general population study by Petta and 
colleagues in Palermo, Italy,28 890 adults (mean age 
53 years) were assessed for NAFLD with transient 
elastography and CAP, with similar cut-off values for 
fibrosis stage and steatosis grade. They identified 
428 (48·1%) of their population to have NAFLD, 27·4% of 
whom had type 2 diabetes or impaired fasting glucose. 
Of the 890 participants, 28 (3·1%) had NAFLD and 
evidence of advanced fibrosis (≥F3). By comparison, only 
1·5% of our cohort had F3–F4 fibrosis. Although no 
ALSPAC participants had known type 2 diabetes, 
HOMA-IR in participants with steatosis (≥S1) in Petta 
and colleagues’ study was similar to that in our S3 group 
(3·2 vs 3·6).28
Our study had limitations. Transient elastography is an 
extensively validated modality with good diagnostic 
ability to detect fibrosis equivalent to stage F2 and 
higher.10,20 However, this ability is lost when attempting to 
differentiate between F0 and F1 fibrosis. As a result, this 
population study could under-report the number of 
participants with fibrosis as we cannot comment on 
those with early F1 fibrosis.10
Although we estimated the prevalence of suspected 
NAFLD to be 20·7%, when evaluating associations with 
transient elastography values equivalent to fibrosis stage 
in multivariable regression, no association was found 
with CAP score alone. Ultimately, the staging cut-off 
values based on transient elastography and cause of 
fibrosis are validated in patients with histologically 
proven advanced liver disease, and caution should be 
applied in interpreting transient elastography results 
indicative of fibrosis in young adults in a general 
population. In this context, the proportion of people with 
advanced fibrosis in our cohort could be an 
overestimation. Full liver screens looking for other 
Participants with fibrosis Unadjusted OR (95% CI) p value Adjusted for Adjusted OR (95% CI) p value
Alcohol consumption*
Low risk 37/1610 (2·3%) Reference ·· CAP, BMI, smoking, social class Reference ··
Hazardous 39/1520 (2·6%) 1·12 (0·71–1·77) 0·63 ·· 1·38 (0·79–2·41) 0·26
Harmful (alcohol use disorder) 20/470 (4·3%) 1·89 (1·09–3·29) 0·02 ·· 2·11 (1·02–4·37) 0·04
Steatosis
S0 69/2795 (2·5%) Reference ·· Excessive alcohol intake*, BMI, 
smoking, social class
Reference ··
S1 6/264 (2·3%) 0·92 (0·40–2·14) 0·84 ·· 0·60 (0·21–1·73) 0·34
S2 3/109 (2·8%) 1·12 (0·35–3·61) 0·85 ·· 1·19 (0·35–4·01) 0·78
S3 16/343 (4·7%) 1·93 (1·11–3·37) 0·02 ·· 0·83 (0·35–1·96) 0·67
Alcohol use disorder and steatosis
No alcohol use disorder or steatosis 27/1231 (2·2%) Reference ·· Smoking, social class Reference 0·13
Steatosis, no alcohol use disorder 10/346 (2·9%) 1·33 (0·64–2·77) 0·45 ·· 1·56 (0·63–3·84) 0·33
Alcohol use disorder, no steatosis 13/368 (3·5%) 1·63 (0·83–3·20) 0·15 ·· 2·05 (0·86–4·91) 0·11
Alcohol use disorder and steatosis 7/94 (7·4%) 3·59 (1·52–8·47) 0·004 ·· 4·02 (1·24–13·02) 0·02
Sex
Male 54/1391 (3·9%) Reference ·· BMI, excessive alcohol intake*, 
smoking, social class
Reference ··
Female 42/2209 (1·9%) 0·48 (0·32–0·72) <0·0001 ·· 0·51 (0·31–0·84) 0·008
OR=odds ratio. CAP=controlled attenuation parameter. *According to AUDIT-C score and the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for alcohol use disorder;23 excessive intake defined as 
hazardous or harmful consumption.
Table 5: Exposures associated with the presence of fibrosis in analysed participants (n=3600)
See Online for appendix
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causes of liver disease, such as viral hepatitis, 
autoimmune hepatitis, and primary biliary cholangitis, 
were not done in our participants. However, the 
prevalence of viral hepatitis in southwest England is low, 
with hepatitis C prevalence in the greater Bristol area 
estimated at 0·31%, according to the Operational 
Delivery Network profile tool of Public Health England. 
In England, of the 571 positive hepatitis C antibody or 
ribonucleic acid tests in 2018–19, less than 5% were in 
15–24 year olds.29 Additionally, the proportion of positive 
laboratory reports for acute or chronic hepatitis B is 
6·8 per 100 000 of the population in the southwest 
region.30 Furthermore, in our large population study, the 
gold standard method of liver biopsy was not ethically 
viable. Therefore, the definitive cause of fibrosis was only 
speculated to be NAFLD in participants with steatosis in 
the absence of harmful alcohol consumption.
The suspected NAFLD prevalence of 20·7% is a 
substantial increase from a sample of the same cohort 
6 years earlier (mean age 17·9 years), when prevalence 
was estimated at 2·5%.6 This previous analysis used 
ultrasound to assess steatosis, and did not include mild 
(S1) steatosis in its definition of NAFLD. Ultrasound has 
been superseded in clinical practice by transient 
elastography and CAP measurement for assessment of 
fibrosis and quantification of steatosis. Therefore, the 
prevalence of NAFLD could have been under-reported 
previously in this cohort. A similar population-based 
cohort study in Australia that used ultrasound 
assessment reported a prevalence of 12·8% for NAFLD.7 
Ultrasound has greater than 90% sensitivity to detect 
steatosis of 30% or more, which corresponds to 
high S1 and low S2 steatosis.31 13·2% of our participants 
had S2–S3 steatosis, and therefore a substantial increase 
in the prevalence of NAFLD in the ALSPAC birth cohort 
seems to have occurred between 18 to 24 years, despite 
differences in methods used for detection.
This study did not collect data on grams of alcohol 
consumed by participants. To compensate for these 
missing data, we risk-stratified our participants using 
AUDIT-C scores and evidence of alcohol use disorder 
into the categories of hazardous and harmful drinking. 
As a result, the true number of participants with excessive 
alcohol consumption might be under-reported. Similarly, 
we did not have data on physical activity to comment on 
its effect as a predictor of steatosis and fibrosis. However, 
physical activity relates closely to our key exposures of 
obesity and adiposity, both of which were shown to be 
positively associated with steatosis around the age of 
24 years.
The ALSPAC birth cohort might not be truly re-
presentative of the wider NAFLD prevalence in the UK. 
The demographic profile of the catchment area population 
in southwest England, and the differential attrition, has 
created an over-representation of affluent groups and an 
under-representation of ethnic minorities.13 Although our 
study found no association between social class and 
increased steatosis and fibrosis, we acknowledge that 
participants that continue to attend our clinics tend to 
have higher-level educational attainment, introducing a 
selection bias.13,14 Furthermore, the southwest region of 
England has the third lowest adult prevalence of obesity 
in the UK, at 23%.32 Therefore, this study might 
underestimate the prevalence of NAFLD in young adults 
for the whole of the UK, and particularly for regions such 
as northeast England, where the prevalence of adult 
obesity is 30%.32
We found obesity to be the strongest factor associated 
with steatosis. Correspondingly, overweight and obese 
BMI and increased adiposity were the most powerful 
predictors of steatosis despite adjustments for excessive 
alcohol consumption, social class, and smoking. These 
findings reflect previous work that identified a dose-
response relationship between BMI and steatosis 
outcomes.33
The prevalence of NAFLD appeared to be greater in 
young men than in young women, a shift from our earlier 
assessment at 17 years, in which prevalence was similar 
across the sexes.6 Interestingly, this prevalence in young 
men was despite proportionally more female participants 
having obesity than male participants (15·0% vs 10·7%), 
which contrasts with national data from Cancer Research 
UK, showing that the prevalence of adult obesity is higher 
in men than women. Part of this discrepancy could be 
due to a slightly greater proportion of men in our cohort 
having increased adiposity compared with women, based 
on waist-to-height ratio (28·6% vs 27·5%). These findings 
are consistent with another large epidemiological study of 
electronic health records, which identified male sex as an 
independent risk factor for NASH and NAFLD.34
Strong evidence exists that alcohol-related liver disease 
is linked to socioeconomic deprivation, and similarly, that 
deprivation is linked to obesity in the paediatric and 
adolescent settings.3,35,36 We found no association between 
the severity of steatosis or fibrosis and socioeconomic 
status. Furthermore, no association was identified 
between smoking and suspected NAFLD, despite smoking 
being a well recognised risk factor for the development of 
NAFLD.37 However, most studies looking at the association 
of smoking with NAFLD have been in middle-aged adults 
(aged 40–60 years), and the effects of smoking might have 
been too premature to be apparent in the young adults of 
our birth cohort.
2·7% of our cohort had evidence of F2-equivalent or 
greater fibrosis. Steatosis combined with alcohol use 
disorder had the highest risk of fibrosis compared with 
alcohol use disorder or steatosis alone. This result 
is reflective of the complex relationship between NAFLD 
and alcohol. Moderate alcohol consumption (<20 g/day) 
has been purported to be protective against steatohepatitis 
in studies of patients with NAFLD.38,39 However, chronic 
alcohol consumption in the context of NAFLD has 
been associated with increased risk of hepatocellular 
carcinoma.40,41 In 2019, a cohort study of UK and US 
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patients with alcohol-related hepatitis that short-term 
mortality was two times greater in patients with obesity.42 
Ultimately in our study, we did not identify any protective 
effect of alcohol consumption on steatosis, and at least 
seven participants had suspected fibrosis in the setting of 
alcohol-related liver disease with steatosis.
Overall our findings have serious public health 
implications for the UK. Half of our participants with 
steatosis had S3 steatosis, which theoretically has the 
greatest association with the risk of NASH, compared 
with lower grades of steatosis. Progression to fibrosis 
ranges between 33% and 40% in the literature once 
NASH is established.43,44 Evidence exists for steatosis or 
non-alcoholic fatty liver progressing to fibrosis, with 
concurrent diabetes a strong risk factor.45 We are not 
aware of any patients with confirmed type 2 diabetes in 
our cohort of young adults, but the mean HOMA-IRs for 
all the steatosis groups were indicative of insulin 
resistance (≥1·68). Although no association was seen 
between HOMA-IR and increasing fibrosis stage in 
participants with suspected NAFLD, HOMA-IR was 
associated with increasing CAP score, supporting the 
concept that insulin resistance is a major facilitator of 
steatosis in the context of NAFLD.46
In conclusion, this study provides evidence that the 
obesity epidemic is affecting the future health of young 
adults in the UK, by increasing their risk of NASH-related 
cirrhosis, hepatocellular carcinoma, and complications 
of metabolic syndrome. Crucially, these outcomes can be 
avoided with stringent public health measures, starting 
with increased awareness of NAFLD among the general 
population. We identified participants in our cohort with 
NAFLD-related fibrosis, but the strongest association 
with increased severity of fibrosis was found in 
participants with harmful alcohol consumption and 
hepatic steatosis.
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